The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome

NACompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Pancreatic Cancer
Interventions
DRUG

Gadobutrol

0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush

DRUG

[F-18]HX4

400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.

DRUG

Gemcitabine

1000 mg/m2/dose on day 1 and 8 in 2 cycles of 21 days (three weeks) each, one cycle before and one cycle after radiochemotherapy. During radiotherapy gemcitabine is administered at 1000 mg/m2/dose on day 1, 8 and 15.

RADIATION

Radiotherapy

A hypofractionated scheme of 15 fractions of 2.4 Gy in three weeks will be applied, combined with the second course of gemcitabine.

PROCEDURE

Pancreaticoduodenectomy

Trial Locations (2)

1105AZ

Academic Medical Center, Amsterdam

3000CA

Erasmus MC, Rotterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Erasmus Medical Center

OTHER

collaborator

Dutch Cancer Society

OTHER

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER